Bicara Therapeutics Inc. BCAX 深 沪
等待开盘 02-11 09:30:00 美东时间
14.97
-0.020
-0.13%
华盛通- 最 高15.44
- 今 开15.01
- 成交量 25.69万股
- 最 低 14.83
- 昨 收 14.99
- 总市值 8.20亿
- 52周最高 19.71
- 市盈率 静 --
- 换手率 0.47%
- 52周最低 7.80
- 委 比 -77.98%
- 总股本 5478.20万
- 历史最高 28.09
- 量 比 0.67
- 振 幅 4.07%
- 历史最低 7.80
- 每 手 1
- 风险率 2.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares
Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created
01-27 05:35
Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares
Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Techn
01-27 05:34
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
BTIG Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $28
BTIG analyst Jeet Mukherjee initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $28.
01-08 21:18
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Bicara Therapeutics Inc. announced that its CEO, Claire Mazumdar, will present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026. The presentation will be webcast live and available for replay on the company’s Investor Relations website. Bicara focuses on developing bifunctional therapies for solid tumors, with its lead drug, ficerafusp alfa, targeting EGFR and TGF-β to improve tumor penetration and efficacy in head and neck cance...
2025-12-15 13:00
Bicara Therapeutics Shares Early Trial Results Backing FDA-Supported Fast-Track Drug
Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract
2025-12-01 20:15
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Bicara Therapeutics GAAP EPS of -$0.67
Bicara Therapeutics press release (BCAX): Q3 GAAP EPS of -$0.67. Cash, Cash Equivalents and Investments: As of September 30, 2025, Bicara had cash, cash equivalents and investments of $407.6 million, ...
2025-11-10 21:51
